Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711–22.
Randomised controlled trial.
Sixteen weeks (treatment period only).
Part of STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder) trials, carried out in 22 centres in the USA; November 1999 to July 2005.
366 adults (aged over 18 years) currently experiencing a DSM-IV major depressive episode associated with bipolar I or bipolar II disorder. Exclusions: history of intolerance or non-response to paroxetine and bupropion; receiving treatment for substance abuse disorder; or requiring addition of, or dose change of, antipsychotic medication.
Paroxetine (10 mg increased up to maximum 40 mg daily), sustained-release bupropion …
Source of funding: National Institute of Mental Health (NIMH). Antidepressants donated by Glaxo Wellcome and GlaxoSmithKline.
Competing interests: None.